MilliporeSigma and The Michael J. Fox Foundation for Parkinson's Research (MJFF) have partnered to research treatments to slow down the progression of Parkinson's disease (PD).
According to the partnership, MilliporeSigma will use its SMCxPRO immunoassay technology to detect low levels of pS65 ubiquitin, a biomarker associated with cell dysfunction in PD patients. This technology will help track the response of different therapeutic options on disease progression, potentially contributing to improved quality of life for patients. The study will be funded by MJFF.
MilliporeSigma, Merck KGaA's life science business, was formed from the merger of EMD Millipore and Sigma-Aldrich. It offers a comprehensive portfolio of life sciences products, including biochemicals, labware, and equipment for various scientific and industrial applications. MilliporeSigma focuses on accelerating access to health by providing tools for research, drug discovery, development, and manufacturing.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.